Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Income from Continuing Operations (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Income from Continuing Operations for 17 consecutive years, with 7900000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 81.46% to 7900000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 365900000.0, a 187.21% decrease, with the full-year FY2025 number at 365900000.0, down 187.43% from a year prior.
  • Income from Continuing Operations was 7900000.0 for Q4 2025 at Myriad Genetics, up from 27400000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 24600000.0 in Q3 2021 to a low of 330500000.0 in Q2 2025.
  • A 5-year average of 44790000.0 and a median of 29300000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 261.84% in 2021, then crashed 800.54% in 2025.
  • Myriad Genetics' Income from Continuing Operations stood at 7600000.0 in 2021, then tumbled by 456.58% to 42300000.0 in 2022, then grew by 26.24% to 31200000.0 in 2023, then tumbled by 36.54% to 42600000.0 in 2024, then skyrocketed by 81.46% to 7900000.0 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Income from Continuing Operations are 7900000.0 (Q4 2025), 27400000.0 (Q3 2025), and 330500000.0 (Q2 2025).